Effects of orally administered tetracycline on the intestinal community structure of chickens and on tet determinant carriage by commensal bacteria and Campylobacter jejuni.

There is a growing concern that antibiotic usage in animal production has selected for resistant food-borne bacteria. Since tetracyclines are common therapeutic antibiotics used in poultry production, we sought to evaluate the effects of oral administration on the resistance of poultry commensal bacteria and the intestinal bacterial community structure. The diversity indices calculated from terminal restriction fragment length polymorphism (T-RFLP) analysis of 16S rRNA amplicons did not indicate significant changes in the cecal bacterial community in response to oxytetracycline. To evaluate its effects on cultivable commensals, Enterococcus spp., Escherichia coli, and Campylobacter spp. were isolated from the cecal droppings of broiler chickens. Enterococcus spp. and E. coli expressed tetracycline MICs of >8 microg/ml and harbored a variety of tet resistance determinants regardless of the tetracycline exposure history of the birds. The enterococcal isolates possessed tetM (61%), tetL (25.4%), and tetK (1.3%), as well as tetO (52.5%), the determinant known to confer a tetracycline resistance phenotype in Campylobacter jejuni. E. coli isolates harbored tetA (32.2%) or tetB (30.5%). Tetracycline MICs remained at <2 microg/ml for Campylobacter isolates before and after tetracycline treatment of the chickens, even though isolates expressing MICs of >16 mug/ml were commonly cultured from flocks that did not receive oxytetracycline. The results imply that complex ecological and genetic factors contribute to the prevalence of antibiotic resistance arising from resistance gene transfer in the production environment.

The effect of mannanoligosaccharides, bambermycins, and virginiamycin on performance of large white male market turkeys.

A study was conducted to evaluate the effects of mannanoligosaccharides (MOS), bambermycins (BAM), and virginiamycin (VIR) on the growth performance of male turkeys. Hybrid Large White male poults were assigned to six dietary treatments: control, MOS, BAM, VIR, MOS+BAM (MB), and MOS+VIR (MV). All diets were formulated to meet NRC (1994) nutrient requirements. There were eight replicate floor pens per treatment with 20 birds per pen reared from 1 to 140 d. Body weight and feed conversion (FC) were collected at 3-wk intervals and at 20 wk of age. Mortality and culled birds were recorded daily. All treatments except MV significantly (P < 0.05) increased 20 wk BW. Body weight was increased at 12 wk by BAM, whereas VIR increased BW at Weeks 12 and 15. All treatments improved FC for Weeks 0 to 3, whereas VIR, MB, and MV improved FC for Weeks 0 to 12 and 0 to 18. There were no treatment effects on cumulative mortality or cull rate. Dietary supplemental MOS, BAM, and VIR resulted in improved growth performance of Large White turkeys. These results indicate that MOS may be utilized as an alternative to antibiotic growth promotants to improve turkey performance.

A novel delivery of oxytetracycline in turkey breeder hens.

A novel product (SQ12) for subcutaneous (SQ) injectable delivery of oxytetracycline (OTC) has been developed for use in livestock. SQ12 employs microfluidic spheres encasing OTC crystals, which allows for longer release of the OTC compared with other injectable antibiotics. The objectives of the study were to determine serum and tissue levels of SQ12 in turkey breeder hens to 14 days postinjection and to evaluate effects of SQ12 on reproductive status. Thirty photostimulated hens were housed in litter floor pens and provided with 14.5 hr of light per day in a curtain-sided facility. Six hens served as untreated controls. Twelve hens per treatment group received SQ injections in the neck with SQ12 at 11.4 (L dose group) or 22.7 mg/kg (H dose group) to assess low and high doses, respectively. Serum samples were obtained from each hen at predose and 6, 12, 24, 48, 72, 96, 168, 240, and 336 hr postinjection. All hens were euthanatized at 14 and 15 days postinjection. One-half of the hens in each treatment group were sampled (liver, lung, kidneys, and breast muscle) for tissue residue levels of OTC. The control group had no detectable OTC in serum or tissues at any sample collection time. There were no detectable serum levels of OTC in either treatment group prior to injection. The average serum concentrations of the L and H dose groups showed similar depletion curves although the H dose group was 42% higher at maximum concentration than the L group. Average tissue concentration of OTC for all tissues sampled from the H dose group was twice that of the L dose group. All tissue levels were below the OTC residue tolerance limit. SQ12 provided an extended source of OTC in serum of turkey breeder hens with no effect on reproductive status. SQ12 may provide for a novel treatment of bacterial infection in turkey breeder hens with longer lasting serum levels compared with other single injectable OTC products.

Effects of hen age, Bio-Mos, and Flavomycin on poult susceptibility to oral Escherichia coli challenge.

The effects of hen age, Escherichia coli, and dietary Bio-Mos and Flavomycin on poult performance from 1 to 21 d were studied. Day-of-hatch BUTA (BIG-6) male poults were gavaged orally (1 mL) with approximately 10(8) cfu/mL E. coli composed of four serotypes or sterile carrier broth. A mixture of the same E. coli cultures was added to the poults' water troughs to attain a concentration of approximately 10(6) cfu/mL on a weekly basis to ensure a continuous bacterial challenge. Within each E. coli split plot treatment group, poults from hens of different ages (33 and 58 wk of age) were fed diets containing Bio-Mos (1 g/kg feed), Flavomycin (2.2 mg active ingredient/kg feed), Bio-Mos plus Flavomycin, or a control diet, in a randomized complete block design. This experiment yielded eight treatments per challenge group. At Weeks 1 and 3, eight birds from each treatment from the E. coli challenged and unchallenged groups were randomly chosen for bacterial sampling of liver and intestinal tissue for coliforms, aerobic bacteria, and Lactobacillus spp. E. coli isolates from tissue samples were O serotyped. During E. coli challenge, dietary Bio-Mos and Flavomycin improved poult BW and BW gains (P < or = 0.05). When poults were not challenged with E. coli, poults from old hens had improved BW and cumulative BW gains over poults from young hens (P < or = 0.05). Cumulative 3-wk BW gains for unchallenged poults from young hens were improved by Bio-Mos and Flavomycin (P < or = 0.05) alone and in combination when compared to the control diet. Two of the four E. coli serotypes administered were recovered. Several serotypes were recovered that were not administered. It may be concluded that dietary Bio-Mos and Flavomycin can improve the overall performance of poults, especially when they are faced with an E. coli challenge.